OssDsign reports sales decline in Q3 2026 results
Medical technology company OssDsign AB has released its third-quarter financial results for 2026, reporting net sales of 35.7 million SEK.
OssDsign AB, a developer of regenerative medical implants, reported net sales of 35.7 million SEK for the third quarter of 2026. This figure represents a decline compared to the 44.0 million SEK recorded during the same period in the previous year.
The company is scheduled to discuss these financial results during an investor webcast today at 11:00 CEST. Investors and stakeholders can access the presentation via the company’s investor relations portal or the provided DNB Carnegie link.
Full details regarding the company’s financial position and operational updates are available in the official Q3 2026 interim report, now accessible on the OssDsign website.